Current Drug Regulatory Status of Advanced Drug Evaluation System in Korea

被引:0
|
作者
Pork I.-S. [1 ]
Kim D.S. [2 ]
机构
[1] Pharmaceutical Standardization and Cardiovascular Drug Division, Drug Evaluation Department, Korea Food and Drug Administration, Seoul
[2] Toxicological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration, Seoul, 122-70, 194 Tongiro, Eunpyeong-gu
关键词
CTD; Drug approval; GMP; GRP; IND; KFDA; Korea;
D O I
10.1177/009286150904300108
中图分类号
学科分类号
摘要
The pharmaceutical industry is a high-risk and high value-added industry, because the risk of failure in research and development is considerable. However, successful development will allow a company to get high returns. The market scale of the pharmaceutical industry has been increasing in the world and the Korean market is changing to focus on quality of life drugs owing to people's increased income levels and changing lifestyles. Drug products are important for the prevention, diagnosis, and treatment of diseases, and the development of drug products has resulted in improved quality of life, health maintenance, and considerable benefits to individuals as well as the national economy. However, since drug products carry the risks of adverse reactions, they have to satisfy the two important criteria of safety and efficacy. Therefore, the Korean government has implemented a drug safety management system, including one for authorization of drug products. Recently, one of the most important issues in the Korean pharmaceutical industry has been the signing of the Korea-US FTA (Free Trade Agreement), which will promote rapid and widespread competition. The pharmaceutical industry will also face the challenges of a more competitive environment. For sustainable growth and development of the Korean pharmaceutical industry in this rapidly changing environment, the balanced harmonization of the industry's strategic R&S efforts and the government's positive policies is essential. © 2009, Drug Information Association. All rights reserved.
引用
收藏
页码:41 / 46
页数:5
相关论文
共 50 条
  • [1] Current Drug Regulatory Status of Advanced Drug Evaluation System in Korea
    Park, In-Sook
    Kim, Deng Sup
    DRUG INFORMATION JOURNAL, 2009, 43 (01): : 41 - 46
  • [2] Current status of the drug safety monitoring system in Korea
    Park, BJ
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2001, 10 (06) : 557 - 560
  • [3] DRUG INTERACTION STUDIES DURING DRUG DEVELOPMENT: CURRENT STATUS AND REGULATORY PERSPECTIVES IN JAPAN
    Sato, Masanobu
    Ishiguro, Akihiro
    Iwata, Daisuke
    Kishi, Tatsuo
    Hirano, Mai
    Hoshino, Motohiro
    Nagai, Naomi
    DRUG METABOLISM REVIEWS, 2014, 45 : 116 - 116
  • [4] The Current Status of Korea Institute of Drug Safety and Risk Management-Korea Adverse Event Reporting System Database in the Republic of Korea
    Oh, S.
    Kim, B.
    Jang, B.
    Kim, D.
    Kim, H.
    Shin, S.
    Chung, S. Y.
    DRUG SAFETY, 2019, 42 (10) : 1207 - 1207
  • [5] Current Status of Drug Problems and Drug Analysis
    Akutsu, Mamoru
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2019, 139 (05): : 693 - 697
  • [6] Polymers for Mucoadhesive Drug Delivery System: A Current Status
    Asane, G. S.
    Nirmal, S. A.
    Rasal, K. B.
    Naik, A. A.
    Mahadik, M. S.
    Rao, Y. Madhusudan
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2008, 34 (11) : 1246 - 1266
  • [7] A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives
    Liu, Peng
    Chen, Guiliang
    Zhang, Jingchen
    MOLECULES, 2022, 27 (04):
  • [8] Advanced science education in the regulatory arena: The Center for Drug Evaluation and research experience at the Food and Drug Administration
    Ajayi, FO
    Wilcox, DF
    Uhl, K
    Quinn, J
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (07): : 711 - 717
  • [9] Current status of the Matson Evaluation of Drug Side Effects (MEDS)
    Matson, Johnny L.
    Cervantes, Paige E.
    RESEARCH IN DEVELOPMENTAL DISABILITIES, 2013, 34 (05) : 1849 - 1853
  • [10] Evaluation of transporters in drug development: Current status and contemporary issues
    Lee, Sue-Chih
    Arya, Vikram
    Yang, Xinning
    Volpe, Donna A.
    Zhang, Lei
    ADVANCED DRUG DELIVERY REVIEWS, 2017, 116 : 100 - 118